Original source (on modern site) | Article images: [1]
Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that's seen as a potential competitor to Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that "we are very encouraged with the results" from an interim analysis of that trial. Topline data are expected late this year. The company is planning a "broad" Phase 3 program that will study MariTide in obesity, diabetes, and obesity-related conditions, Bradway said. It's already gearing up to make large amounts of the drug, initiating activities "to further expand manufacturing capacity with both clinical and commercial supply in mind," he said. Amgen shares were up 13% in post-market trading. STAT+ Exclusive Story Already have an account? Log in
Already have an account? Log in Already have an account? Log in View All Plans
Get unlimited access to award-winning journalism and exclusive events. Subscribe
National Biotech Reporter Elaine Chen covers biotech and co-writes the The Readout newsletter. To submit a correction request, please visit our Contact Us page.This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Elaine Chen
![[1]](image.php?loc=JP&i=https://www.statnews.com/wp-content/uploads/2024/02/AdobeStock_439672774_Editorial_Use_Only-1024x576.jpeg){kind=link}